Psychedelic Clinical Trial for Alcohol Use Disorder  

Psychedelic Clinical Trial for Alcohol Use Disorder 

Clearmind Medicine is looking for healthy volunteers aged 18-60 to take part in a trial using MEAI – a novel non-hallucinogenic psychedelic.  

We are studying the tolerability and safety of MEAI in healthy volunteers. Participants will receive single doses of MEAI. The study involves around 36-hour admittance at the facility.  

The clinical trial will take place in one of 4 facilities:   

1. Johns Hopkins School of Medicine, Baltimore, MD, USA.  

• Call 410-550-7923 
  

2. Yale School of Medicine, Department of Psychiatry, New Haven, CT, USA.  

• Principal investigator: Anahita Bassir Nia, MD. 
• Call 203-932-5711 X1-5314 or 203-974-7324 abn.lab@yale.edu
  

3. Hadassa-University Medical Centre, Jerusalem, Israel 

• Principal Investigator: Prof. Yossi Karko. 
• Call 050-5172717 or netanelt@hadassah.org.il 
  
  4. Tel Aviv Sourasky Medical Center. Tel-Aviv, Israel
  
• Principal Investigator: Dr. David Zeltser
• Call the Office 03-6973776 or Study Coordinator 052-4266763 or WhatsApp 052-426249 

To take part, you must: 

• Be a healthy volunteer willing to abstain from alcohol for 72 hours (3 days) before the trial.  

To take part, you must not: 

• Have a major mental health concern  
• Have abnormal liver function, uncontrolled hypertension or increased heart rate 

If you have any questions, please contact info@clearmindmedicine.com.